GSK1292263

SKU: orb1227105

Description

GSK1292263 is a novel potent, selective GPR119 agonist, elevates circulating glucose-dependent insulinotropic peptide, GLP-1 and peptide tyrosine-tyrosine in nonclinical models of diabetes, with no effect on plasma glucose.Dyslipidemia Phase 2 Discontinued(In Vivo):GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats.

Key Properties

• CAS Number: 1032823-75-8
• MW: 456.5578
• Purity: >98% (HPLC)
• Formula: C₂₃H₂₈N₄O₄S
• SMILES: O=S(C1=CC=C(C2=CC=C(OCC3CCN(C4=NC(C(C)C)=NO4)CC3)C=N2)C=C1)(C)=O
• Target: GPR119
• Solubility: DMSO: ≥ 30 mg/mL

Bioactivity

• In Vivo:
  GSK1292263 upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats. Animal model: Male neonatal Streptozotocin (STZ)-induced SD rats (7 weeks of age). Dosage: 30 mg/kg. Administration: Orally given; once a day for 2 weeks. Result: The AUC of plasma glucose (AUCPG) in the single treatment of the GSK1292263 group was numerically lower than that of the vehicle group, but the effect was modest.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

GSK 1292263 | GSK-1292263

Quick Database Links

Gene Symbol

GPR119